REVERSE-Long COVID-19 With Baricitinib Study | MicrobiomeTrials← Back to trialsNCT05858515
REVERSE-Long COVID-19 With Baricitinib Study
WITHDRAWNPHASE3INTERVENTIONAL
Trial Details
Start: 2024-10-21Est. Completion: 2027-12-31
Enrollment target: 0 participants Locations- University of California San Francisco, San Francisco, California, United States
- Yale University, New Haven, Connecticut, United States
- Emory University, Atlanta, Georgia, United States
- University of Minnesota, Minneapolis, Minnesota, United States
- Vanderbilt University, Nashville, Tennessee, United States
- Vanderbilt University Medical Center, Nashville, Tennessee, United States
Other microbiome trials you might be interested in
Post-Acute COVID-19 Syndrome
Background:
SARS-CoV-2 is the virus that causes COVID-19. Some people who recover from an acute COVID-19 infection may …
Bethesda, United StatesEst. completion Jan 1, 2028
COVID-19
In many national Coronavirus Disease 2019 (COVID-19) response plans, including in Kenya and Cameroon, antigen detection …
Yaoundé, CameroonCompleted Oct 31, 2022
Recruiting
Respiratory Distress Syndrome, Adult
Acute Respiratory Distress Syndrome (ARDS) is a serious condition that occurs as a complication of medical and surgical …
Los Angeles, United StatesEst. completion Jun 30, 2026